Emyria

Emyria's approach combines direct patient care with pioneering drug development to address significant, global unmet needs in mental health and select neurological conditions.

We believe this represents a significant opportunity for patients and our investor supporters.

Investing in Emyria means supporting a company that is not only committed to advancing mental health care but is also strategically positioned to lead in care, treatment, and data innovation. Join us as we set new standards and create lasting impact in the healthcare industry.

Emyria is committed to delivering high-quality mental health care and developing groundbreaking treatments. With substantial financial support and strategic partnerships, we are well-positioned to expand patient access and drive sustainable growth, creating value for our shareholders and making a meaningful impact on mental health care globally.

Why Invest in Emyria?

Meet the Team

Announcements

New investors

Corporate Governance

Updates

About Emyria

Home

Pipeline

Montserrat

 Leveraging Australia's unique regulatory environment, we are evaluating MDMA-assisted therapy to gather crucial clinical data and develop new treatments.

Psilocybin-Assisted Therapy for Depression:

 We are pioneering psilocybin-assisted therapy for treatment-resistant depression, setting new benchmarks in mental health care.

 Our pipeline includes "MDMA 2.0," a pro-social drug for assistive therapies, and an "anti-dyskinesia" medication for Parkinson's disease.

 Our Empax Centres are state-of-the-art facilities designed to deliver advanced mental health therapies. We are expanding these centers to enhance patient access and outcomes, integrating cutting-edge technology and compassionate care.

Financial Growth: Achieved over $1 million in clinical billings for the first time, with a 60% increase in mental health service revenues, demonstrating strong traction in our core business areas.


Strategic Expansion: Opened the first Empax Centre, equipped with advanced technology for superior patient care and research. We are expanding nationally to meet growing demand for our services.


Collaborative Research: Partnered with Reach Wellness to study MDMA-assisted therapy for first responders with PTSD, and selected as a key site for the "IMPACT-2" trial on PTSD, showcasing our research capabilities.

We provide specialised mental health services at our state-of-the-art Empax Centre, focusing on conditions like PTSD and treatment-resistant depression. Our team includes Australia's first female Authorised Prescriber for MDMA-assisted therapy, enhancing our capacity for innovative treatments.

Emyria is at the forefront of developing new therapies, including MDMA-assisted treatments and a pipeline of patentable MDMA-like compounds. Our collaboration with the University of Western Australia supports the creation of novel drug candidates, positioning us as a global leader in MDMA-related treatments. 

We capture robust real-world data to refine our therapy protocols and support our drug development programs. This data not only improves patient outcomes but also s

The Empax Centre is Emyria's state-of-the-art facility dedicated to advancing mental health care. It offers specialised services for conditions like PTSD, utilising advanced technology for superior patient care and data-driven research. The centre is a hub for innovative treatments, including MDMA-assisted therapy, and plays a key role in our clinical service expansion.



Learn more